Switch to:
Novo Nordisk A/S (NYSE:NVO)
Research and Development
$2,435 Mil (TTM As of Sep. 2014)

This is the expense the company spent on research and development. Novo Nordisk A/S's research and development for the three months ended in Sep. 2014 was $633 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2014 was $2,435 Mil.


Definition

This is the expense the company spent on research and development.

Novo Nordisk A/S Research & Development for the trailing twelve months (TTM) ended in Sep. 2014 was 655.273796398 (Dec. 2013 ) + 586.884031123 (Mar. 2014 ) + 560.507464319 (Jun. 2014 ) + 632.650587808 (Sep. 2014 ) = $2,435 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Novo Nordisk A/S Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
Research & Development 7918081,1191,6691,4251,5401,7031,7031,9162,156

Novo Nordisk A/S Quarterly Data

Jun12Sep12Dec12Mar13Jun13Sep13Dec13Mar14Jun14Sep14
Research & Development 432452565462480501655587561633
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK